Sign inCreate account

Report workspace

Add to folder
NCT01677754COMPLETEDanonymous

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease

Sponsor

Source record

Hoffmann-La Roche

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

RO4602522 is an investigational compound targeting mechanisms associated with Alzheimer's disease pathology, potentially modulating neurotransmitter systems involved in cognitive function.

Indication / condition

AI-normalized

Alzheimer's Disease

Intervention

Source record

RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine

Source & freshness

Source record

NCT ID

NCT01677754

Original source

ClinicalTrials.gov

Source last updated

May 30, 2017

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01677754

Title

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease

Sponsor

Hoffmann-La Roche

Status

COMPLETED

Phase

Phase 2

Condition raw

Alzheimer's Disease

Condition normalized

Alzheimer's Disease

Modality raw

small molecule

Modality normalized

small molecule

Target raw

RO4602522 is an investigational compound targeting mechanisms associated with Alzheimer's disease pathology, potentially modulating neurotransmitter systems involved in cognitive function.

Target normalized

RO4602522 is an investigational compound targeting mechanisms associated with Alzheimer's disease pathology, potentially modulating neurotransmitter systems involved in cognitive function.

Interventions

RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine

Public preview

Source record

RO4602522, developed by Hoffmann-La Roche, is positioned in the competitive landscape of Alzheimer's disease therapies, which is characterized by a high unmet need and significant market potential. The drug is being evaluated as an add-on therapy to existing acetylcholinesterase inhibitors and memantine, targeting patients with moderate severity Alzheimer's disease. Given the aging global population and the increasing prevalence of Alzheimer's disease, successful outcomes from this trial could lead to a substantial market opportunity. The competitive landscape includes established therapies and emerging candidates, necessitating a robust efficacy and safety profile to differentiate RO4602522. Diligence should focus on the trial's results, potential regulatory pathways, and the landscape of existing patents to assess freedom to operate and potential barriers to market entry.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT01677754

Status

COMPLETED

Phase

Phase 2

Sponsor

Hoffmann-La Roche

Executive brief

Investment-Ready Snapshot

RO4602522, developed by Hoffmann-La Roche, is positioned in the competitive landscape of Alzheimer's disease therapies, which is characterized by a high unmet need and significant market potential. The drug is being evaluated as an add-on therapy to existing acetylcholinesterase inhibitors and memantine, targeting patients with moderate severity Alzheimer's disease. Given the aging global population and the increasing prevalence of Alzheimer's disease, successful outcomes from this trial could lead to a substantial market opportunity. The competitive landscape includes established therapies and emerging candidates, necessitating a robust efficacy and safety profile to differentiate RO4602522. Diligence should focus on the trial's results, potential regulatory pathways, and the landscape of existing patents to assess freedom to operate and potential barriers to market entry.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 30, 2017
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01677754

Indication

Alzheimer's Disease

Modality

small molecule

Target

RO4602522 is an investigational compound targeting mechanisms associated with Alzheimer's disease pathology, potentially modulating neurotransmitter systems involved in cognitive function.

Intervention

RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.